Previous 10 | Next 10 |
– MAT9001 program progressing ahead of schedule – – Additional head to head data vs. Vascepa® expected in 2020 – – NIH-funded Phase 1/2 EnACT trial of MAT2203 in cryptococcal meningitis to commence in Q4 2019 – – Management t...
BEDMINSTER, N.J., July 30, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live webcast on Tuesday, August 13, 2019 at 8:00 a.m. ET to discuss operat...
The FDA has designated Matinas BioPharma's (NYSEMKT: MTNB ) MAT2203 a Qualified Infectious Disease Product for Fast Track review for the three new indications: the prevention of invasive fungal infections due to immunosuppressive therapy, treatment of invasive candidiasis and treatment of ...
BEDMINSTER, N.J., July 25, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has designated MAT2203, Matinas’ proprietary oral amphotericin B pr...
Baxter International (NYSE: BAX ) initiated with Sector Weight rating at KeyBanc. More news on: Baxter International Inc., Kadmon Holdings, Inc., Matinas BioPharma Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
"Americans will put up with anything provided it doesn't block traffic. ” ― Dan Rather Today, we look at a small ' Tier 4 ' biopharma concern that has had a volatile ride in its five years as a public company. Company Overview: Matinas BioPharma ( MTNB ) IPO’d...
BEDMINSTER, N.J., June 03, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer , has been invited to present at the 9 th Annual LD Micro Invitationa...
– Efficacy of oral delivery of amphotericin B (MAT2203) demonstrated comparable efficacy to IV amphotericin, with similar survival of animals and reduction in fungal burden – – Cryptococcal meningitis is one of the most frequent and opportunistic infections in Hum...
BEDMINSTER, N.J., May 21, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that its abstract of preclinical data of MAT2501, an orally administered, lipid nano-crystal (“LNC”) formulati...
Sydney, Australia (ABN Newswire) - In this segment of The Ellis Martin Report, Ellis speaks with Jerome Jabbour, the CEO of Matinas Biopharma (NYSE:MTNB). The company announced a research collaboration with ViiV Healthcare to evaluate formulation of antiviral drug candidates. Additionally, Mr...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
A look at the top 10 most actives in the United States Kintara Therapeutics Inc. (KTRA) rose 63.3% to $0.164 on volume of 223,092,889 shares C3is Inc. (CISS) rose 24.2% to $0.0508 on volume of 148,576,579 shares Nikola Corporation (NKLA) fell 8.4% to $0.8918 on volume of 128,870,418 share...
A look at the top 10 most actives in the United States Kintara Therapeutics Inc. (KTRA) rose 99.9% to $0.2007 on volume of 121,318,217 shares Next.e.GO N.V. (EGOX) rose 30.8% to $0.034 on volume of 63,981,361 shares C3is Inc. (CISS) rose 20.8% to $0.0494 on volume of 63,446,681 shares I...
BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrysta...